Assessment of direct costs attributed to the clinical management of children with inflammatory bowel disease in New Zealand
Journal of Pediatric Gastroenterology and Nutrition · 2026
DOI: 10.1002/jpn3.70228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Angharad Vernon-Roberts und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Otago Christchurch, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Health Care Costs, Inflammatory Bowel Diseases, Crohn Disease. Die Arbeit nennt 45 Literaturangaben. Gefördert von: New Zealand Society of Gastroenterology, Cure Kids.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
The clinical management of children with inflammatory bowel disease (IBD) incurs a substantial economic burden. No recent data are available for costs within New Zealand, thereby hindering appropriate allocation of resources. The aim of this study was to assess direct health‐care costs for children with IBD in the South Island of New Zealand.
Methods
This retrospective study included children with IBD managed at Christchurch Hospital (2018–2021), with a minimum 12‐month follow‐up. All IBD‐related clinical events were assigned unit costs in New Zealand Dollars (NZD) as well as an equivalent in United States dollars (USD) and Euro (€). Per‐patient costs were estimated using follow‐up duration. Nonparametric analysis examined associations with independent variables.
Results
Seventy‐five children were included: mean age 12.4 years (standard deviation 3.1), 34 (45%) female, 63 (84%) with Crohn's disease (CD). Overall, there were ≈150 person‐years of follow‐up incurring total costs of $3,107,073 ($1,864,857 USD, €1,598,042). The median annual cost per child was $13,674 (interquartile range $7220–$27,714), ($8209 USD, €7034). Biologic drugs and related costs contributed most to expenditure (64%). There was no difference in annual costs between those with CD (median $14,360 [8621 USD, €7388]) and ulcerative colitis/IBD‐unclassified (median $13,194 [$7920 USD, €6788]) or for any cost category (all p > 0.05). Annual costs were higher for those receiving biologics ( p < 0.001), but being on biologics did not influence other cost categories. Higher outpatient and investigation costs were associated with shorter time since diagnosis ( p < 0.001).
Conclusions
There was wide variation in annual per‐patient costs for IBD management in this group with a consistent cost driver being biologic associated expenditure. This data contributes to the wider evidence base that drug costs are the primary driver of hospital care expenditure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Otago Christchurch, Christchurch, New Zealand.
ORCID-Profile: Angharad Vernon-Roberts, Chris M Frampton, Andrew S Day
Förderung
- New Zealand Society of Gastroenterology
- Cure Kids
Zitieren
APA
Vernon-Roberts, A., Frampton, C. M., & Day, A. S. (2026). Assessment of direct costs attributed to the clinical management of children with inflammatory bowel disease in New Zealand. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70228
Vancouver
Vernon-Roberts A, Frampton CM, Day AS. Assessment of direct costs attributed to the clinical management of children with inflammatory bowel disease in New Zealand. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70228
BibTeX
@article{VernonRoberts2026,
author = {Vernon-Roberts, Angharad and Frampton, Chris M and Day, Andrew S},
title = {Assessment of direct costs attributed to the clinical management of children with inflammatory bowel disease in New Zealand},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70228}
}
EUVIMED